Poke survives a Roblox scenario of growing up with criminal parents over 100 intense in-game days.
OpenAI president Greg Brockman has publicly called it “a big model feel — not an incremental improvement.” That matters, ...
Mayor Zohran Mamdani delivered his 100-day address at a concert venue in Queens. He highlighted his accomplishments and was joined by a not-so-surprising guest. By Dana Rubinstein and Olivia Bensimon ...
Zohran Mamdani says he is just getting started. Having just checked off the first 100 days of his administration leading America’s largest city, New York’s mayor told a roaring crowd of supporters, ...
Mayor Zohran Mamdani threw himself a great big bash to celebrate his first 100 days in office, and even launched a website so his faithful comrades can track his “achievements” across the city — ...
NEW YORK (WABC) -- Friday marks 100 days since Mayor Zohran Mamdani took office, which is often seen as a benchmark for a new administration. It's an indication of a leader's management style, their ...
NEW YORK (AP) — In his first 100 days in office, New York City Mayor Zohran Mamdani has governed with a star power unusual in politics. Crowds of supporters show up to his news conferences. Basic ...
NEW YORK (AP) — In his first 100 days in office, New York City Mayor Zohran Mamdani has governed with a star power unusual in politics. Appeals court says Trump’s asylum ban at the border is illegal, ...
Today is New York City Mayor Zohran Mamdani's 100th day in office, a key milestone for his administration and ambitious policy agenda. Mamdani moved quickly to deliver some of his key campaign ...
In his first one hundred days as mayor, Zohran Mamdani has realized that New Yorkers — and all Americans — need to see the government working for them. Zohran Mamdani greeting workers at the site of ...
We are now 100 days into the Zohran Mamdani era – a milestone the city’s youngest mayor in a century is commemorating with signature enthusiasm and communication skills. On Sunday, he’ll deliver a ...
FDA issued a second complete response letter denying approval for Replimune’s RP1 melanoma immunotherapy The treatment was under review for use with Bristol Myers Squibb’s (BMY) Opdivo Regulatory ...